Meanwhile, based on the microarray assay results, SCD-1 is expected as a potential therapeutic target of the GC combination for ameliorating hepatic lipid accumulation in NAFLD. The gene discussed is SCD; the disease is metabolic dysfunction-associated steatotic liver disease.